1h Free Analyst Time
The premature ejaculation treatment market is forecasted to grow by USD 1.52 billion during 2024-2029, accelerating at a CAGR of 8.6% during the forecast period. The report on the premature ejaculation treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high efficacy of off-label premature ejaculation drugs, increasing demand for topical drug therapies for premature ejaculation treatment, and growing risk factors causing premature ejaculation.
The premature ejaculation treatment market is segmented as below:
By Route Of Administration
- Oral
- Topical
By Drug Class
- SSRIs
- PDE5 inhibitors
- Amide anesthetics
- Others
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the premature ejaculation treatment market covers the following areas:
- Premature Ejaculation Treatment Market sizing
- Premature Ejaculation Treatment Market forecast
- Premature Ejaculation Treatment Market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Route of Administration
9 Market Segmentation by Drug Class
10 Customer Landscape
11 Geographic Landscape
12 Drivers, Challenges, and Opportunity/Restraints
13 Competitive Landscape
14 Competitive Analysis
15 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global premature ejaculation treatment market: A. Menarini Industrie Farmaceutiche Riunite Srl, Absorption Pharmaceuticals LLC, Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., Aytu BioPharma Inc., Bayer AG, Eli Lilly and Co., Futura Medical Plc, GlaxoSmithKline Plc, Johnson and Johnson Inc., LloydsPharmacy, NeuroHealing Pharmaceuticals Inc., Niksan Pharmaceutical, Pfizer Inc., Plethora Solutions Ltd., Prinston Pharmaceutical Inc., Ralington Pharma LLP, Sunrise Remedies Pvt. Ltd., Tabuk Pharmaceuticals, and Veru Inc..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is advent of nanotechnology in premature ejaculation treatment drugs."
According to the report, one of the major drivers for this market is the high efficacy of off-label premature ejaculation drugs.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- A. Menarini Industrie Farmaceutiche Riunite Srl
- Absorption Pharmaceuticals LLC
- Alembic Pharmaceuticals Ltd.
- Amneal Pharmaceuticals Inc.
- Aytu BioPharma Inc.
- Bayer AG
- Eli Lilly and Co.
- Futura Medical Plc
- GlaxoSmithKline Plc
- Johnson and Johnson Inc.
- LloydsPharmacy
- NeuroHealing Pharmaceuticals Inc.
- Niksan Pharmaceutical
- Pfizer Inc.
- Plethora Solutions Ltd.
- Prinston Pharmaceutical Inc.
- Ralington Pharma LLP
- Sunrise Remedies Pvt. Ltd.
- Tabuk Pharmaceuticals
- Veru Inc.
